Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$5.95	-0.42%	273.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$5.95	-0.4%	273.58K
3
4
5
6

AVIR

AVIR

No Data Available

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel